Actively Recruiting
Study of PI3K Inhibitors Linperlisib and Duvelisib for Treating Relapsed or Resistant Indolent TNK-Cell Lymphomas
Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2025-08-12
51
Participants Needed
1
Research Sites
100 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of PI3K inhibitors for treating relapsed or refractory indolent TNK-cell lymphomas, a group of slow-growing but currently incurable blood cancers originating from T or NK cells. This open-label, prospective clinical trial aims to assess the feasibility, effectiveness, and safety of these treatments in patients whose disease has not responded to first-line therapies and who have limited options. Participants will receive one of two PI3K inhibitor drugs Linperlisib at 80mg once daily orally or Duvelisib at 25mg twice daily orally, given in 28-day cycles. Treatment will continue for up to 24 cycles unless the disease progresses, there is no response within the first six cycles, or intolerable side effects occur. Effectiveness will be assessed after each cycle during the first year, then every two cycles thereafter. During the study, patients will undergo regular evaluations including response assessments to measure overall response rate, safety monitoring, and other outcomes such as complete remission rate and progression-free survival, tracked for up to five years. The study involves ongoing monitoring for treatment effects and safety to better understand these drugs impact on this patient population.
CONDITIONS
Brief Title
PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Research Team
S
Shuhua Yi, Doctor
L
Lugui Qiu, Doctor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here